BioSpace News Archive

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1st and 2nd, 2021. Jack Kenny, Chief Executive Officer, pre-recorded a fireside chat on Tuesday, November 16, 2021.

ncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and statins as a potential therapeutic treatment approach for chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC).

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received authorization from the United States Food and Drug Administration (FDA) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with amyotrophic lateral sclerosis (ALS).

Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D. and a team from Duke University School of Medicine will present clinical data at the 2021 Society for Neurology (SNO) Annual Meeting.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Piper Sandler 33rd Annual Healthcare Conference.

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m. ET.

Immunic, Inc. (Nasdaq: IMUX), today announced the first patient enrolled in its phase 3 ENSURE program of lead asset, vidofludimus calcium (IMU-838), the company’s selective oral DHODH inhibitor, in patients with relapsing multiple sclerosis (RMS).

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, is scheduled to participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 2, 2021.